Please login to the form below

Not currently logged in

f-star wins €15m investment

Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board

f-star, a company developing antibody-based products, has secured €15m of new financing.

The investment initiative was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star's existing investors, Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management, also participated in the round.

As a result of the financing SR One partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star's supervisory board.

Harland said: "f-star has shown that its Modular Antibody Technology platform can generate multiple high affinity biotherapeutics against targets of varying precedence and novelty in both single- and bi-specific formats.

"We believe the platform has the potential to generate numerous novel differentiated biologics with advanced efficacy, tissue penetration and targeting capabilities compared to traditional antibodies and are excited to be part of the next stage of the company's development," she added.

13th April 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....